Related Experiment Videos
[Serotonin syndrome. Which treatment and when?]
E Jaunay1, V Gaillac, J D Guelfi
1C.H. Sainte-Anne, Service du Pr. Guelfi, 100 rue de la santé, F75014 Paris. e.jaunay@caramail.com
Abstract:
A TOXIC REACTION: Prevalence of the serotonin syndrome is increasing and can be fatal. The physiopathological hypothesis is principally supported by excess stimulation of the central (5HT1a) serotonin receptors. There are various serotonin drugs and associations implied. Monoamine oxidase inhibitors appear to be the major culprits. RECENTLY REVISED CLINICAL DIAGNOSIS FACTORS: The classical triad of neuropsychiatric, neuromuscular and neurovegetative symptoms, described in 1991 by Sternbach, has recently been modified. The syndrome is however protein-like and differential diagnosis remains the neuroleptic malignant syndrome. FIRST-LINE THERAPEUTIC MEASURES: Prevention of the syndrome and its early discovery are essential. Withdrawal of the imputable drugs often resolves the symptoms within 24 hours. Symptomatic and supportive care remains the pillar to treatment. ORIENTATION TOWARDS SPECIFIC TREATMENTS: Several non-selective anti-serotonin treatments have been tested without much success. In the absence of prospective studies, current therapeutic strategies rely on case reports demonstrating the relative efficacy of cyproheptadine and chlorpromazine. The proposed treatment, as soon as severe or persisting symptoms are observed, is administration of 8 to 30 mg cyproheptadine per os, and in the case of failure or contraindication, followed by 50 to 100 mg of intramuscular chlorpromazine, renewed when necessary.
Insights
Serotonin syndrome, a potentially fatal toxic reaction, is increasingly prevalent due to excessive central serotonin receptor stimulation. Early diagnosis and drug withdrawal are key, with cyproheptadine and chlorpromazine offering specific treatment options.
Area of Science:
- Pharmacology
- Toxicology
- Neuroscience
Context:
- Serotonin syndrome prevalence is rising, posing a significant health risk.
- The condition is primarily linked to excessive stimulation of central serotonin 5HT1a receptors.
- Monoamine oxidase inhibitors are frequently implicated as causative agents.
Purpose:
- To review the increasing prevalence and pathophysiology of serotonin syndrome.
- To discuss revised diagnostic criteria and differential diagnoses, including neuroleptic malignant syndrome.
- To outline current and proposed therapeutic strategies for managing serotonin syndrome.
Summary:
- The physiopathology of serotonin syndrome involves overstimulation of central 5HT1a receptors, with monoamine oxidase inhibitors being common culprits.
- Revised diagnostic factors expand on Sternbach's classical triad (neuropsychiatric, neuromuscular, neurovegetative symptoms).
- Early detection and drug withdrawal are crucial; symptomatic care is foundational, with cyproheptadine and chlorpromazine as targeted treatments for severe cases.
Impact:
- Highlights the need for increased awareness and prompt recognition of serotonin syndrome.
- Provides guidance on updated diagnostic approaches and differential diagnosis.
- Offers evidence-based recommendations for specific pharmacological interventions in severe or persistent cases.